Trevi Therapeutics, Inc. (TRVI) News
Filter TRVI News Items
TRVI News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
TRVI News Highlights
- For TRVI, its 30 day story count is now at 8.
- Over the past 26 days, the trend for TRVI's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- ESP, LUNG and MD are the most mentioned tickers in articles about TRVI.
Latest TRVI News From Around the Web
Below are the latest news stories about TREVI THERAPEUTICS INC that investors may wish to consider to help them evaluate TRVI as an investment opportunity.
Trevi Therapeutics, Inc.'s (NASDAQ:TRVI) top owners are private equity firms with 35% stake, while 32% is held by hedge fundsKey Insights The considerable ownership by private equity firms in Trevi Therapeutics indicates that they collectively... |
Trevi Therapeutics to Participate in Upcoming June ConferencesTrevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for difficult to treat patients with chronic cough in idiopathic pulmonary fibrosis (IPF), other chronic cough indications, and prurigo nodularis, today announced senior management will attend and participate in the following conferences in June. In addition, Toby Maher, MD, Professor of Medicine and Director of Interstitial Lung Disease at Keck |
Trevi Therapeutics Announces Publication of Positive Data from the CANAL Trial in IPF Chronic Cough in NEJM EvidenceTrevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for difficult to treat patients with chronic cough in idiopathic pulmonary fibrosis (IPF), other chronic cough indications, and prurigo nodularis, today announced the positive results from the Phase 2 CANAL trial in adults with IPF chronic cough has been published in NEJM Evidence. |
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q1 2023 Earnings Call TranscriptTrevi Therapeutics, Inc. (NASDAQ:TRVI) Q1 2023 Earnings Call Transcript May 11, 2023 Trevi Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.06, expectations were $-0.07. Operator: Good afternoon and welcome to the Trevi Therapeutics’ Q1 2023 Earnings Conference Call. [Operator Instructions] Please note this event is being recorded. Various remarks that management makes during this […] |
Q1 2023 Trevi Therapeutics Inc Earnings CallQ1 2023 Trevi Therapeutics Inc Earnings Call |
Trevi Therapeutics Announces First Quarter 2023 Financial Results and Provides Business UpdateTrevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for difficult to treat patients with chronic cough in idiopathic pulmonary fibrosis (IPF), other chronic cough indications and prurigo nodularis (PN), today announced financial results for the quarter ended March 31, 2023, as well as provided business updates. |
Is a Surprise Coming for Trevi Therapeutics (TRVI) This Earnings Season?Trevi Therapeutics (TRVI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. |
Trevi Therapeutics to Present at Upcoming Yale Innovation Summit 2023Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for difficult to treat patients with chronic cough in idiopathic pulmonary fibrosis (IPF), other chronic cough indications, and prurigo nodularis, today announced its participation at the upcoming Yale Innovation Summit taking place from May 31 – June 1 at the Yale School of Management. The Company will present on its differentiated central and |
Trevi Therapeutics to Report Q1 2023 Financial Results and Provide a Corporate Update on May 11, 2023Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, and for the treatment of prurigo nodularis, today announced that senior management will host a conference call and live audio webcast on Thursday, May 11, 2023, at 4:30 p.m. ET, to provide a corporate update and review the C |
Trevi Therapeutics Announces Two Presentations on the Phase 2 CANAL Data at the ATS 2023 International ConferenceTrevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, today announced data will be presented from two scientific abstracts on the phase 2 CANAL trial in IPF chronic cough at the ATS 2023 International Conference, organized by the American Thoracic Society, being held in Washing |